JPRN-UMIN000010798
Recruiting
Phase 3
Photodynamic diagnosis of non muscle invasive bladder cancer using fluorescence cystoscopy with oral administration of 5-aminolevulinic acid(5-ALA) - Photodynamic diagnosis of non muscle invasive bladder cancer
Department of urology and Andrology, Kansai Medical University0 sites30 target enrollmentMay 24, 2013
Conditionson muscle invasive bladder cancer
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- on muscle invasive bladder cancer
- Sponsor
- Department of urology and Andrology, Kansai Medical University
- Enrollment
- 30
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •patient who has potential complication of local disorder and systematic absorption of 5\-ALA such as solar photosensitivity and liver dysfunction
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Photodynamic diagnosis involving extracorporeal treatment with hexaminolevulinate for bladder cancer cells in surveillance of non muscle invasive bladder cancerbladder cancerJPRN-UMIN000038906ara Medical University162
Completed
Phase 1
Feasibility study of in vivo photodynamic diagnosis using 5ALA for head and neck or gastrointestinal cancerHead and neck or Gastrointestinal cancerJPRN-UMIN000013791ational Cancer Center Hospital East16
Unknown
Not Applicable
Intraoperative Photodynamic Diagnosis study by fluorescent labeling with 5-aminolevulinic acid in Endocrine SurgeryThyroid, parathyroid and adrenal diseasesJPRN-UMIN000023246Endocrine surgery, Nippon Medical School60
Completed
Phase 1
The safety and efficacy of photodynamic diagnosis with SPP-006 at staging laparoscopy for advanced gastric cancer. Prospective multi-center trial.JPRN-jRCT2091220225Osaka University Hospital30
Completed
Phase 3
The efficacy and safety of photodynamic diagnosis with SPP-005 at staging laparoscopy for advanced gastric cancer. Prospective multi-center trial.large type 3 or type 4 gastric cancerJPRN-jRCT2091220309Osaka University Hospital105